<DOC>
	<DOCNO>NCT01493310</DOCNO>
	<brief_summary>This trial find best dose mifepristone give together nab-paclitaxel ( Abraxane ) base side effect two drug patient advance breast cancer . Patients randomized receive nab-paclitaxel without mifepristone first treatment cycle . After first cycle , patient receive nab-paclitaxel mifepristone disease worsen experience unacceptable side effect . This study test 4 dos mifepristone combination nab-paclitaxel . The study first test low dose small group patient bad side effect , high dos test .</brief_summary>
	<brief_title>Nab-paclitaxel ( Abraxane ) With Without Mifepristone Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Patients must metastatic ( stage IV ) unresectable ( remove surgery ) stage III breast cancer Patients must evaluable disease Patients may receive adjuvant chemotherapy four prior chemotherapy regimens metastatic locally recurrent disease receive prior nabpaclitaxel mifepristone therapy metastatic disease Patients estrogen receptor ( ER ) and/or progesterone receptor ( PR ) positive must develop metastatic disease adjuvant hormonal therapy progression disease least one hormonal therapy advance disease ) may receive unlimited prior hormonal therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ( Karnofsky &gt; 60 % ) Absolute neutrophil count &gt; = 1,500/mL Platelets &gt; = 100,000/mL Total bilirubin = &lt; institutional upper limit normal ( ULN ) AST ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /ALT ( serum glutamic pyruvate transaminase [ SGPT ] ) = &lt; 2.5 X institutional ULN Creatinine = &lt; institutional ULN OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Morning cortisol &gt; = institutional normal Negative serum urine pregnancy test require woman childbearing potential ( able get pregnant ) Women childbearing potential men sexually active must agree use two form birth control prior study entry duration study participation Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier Patients may receive investigational drug treatment Patients know brain metastasis eligible long complete radiation brain corticosteroid therapy least 4 week History allergic reaction compound similar mifepristone paclitaxel/nabpaclitaxel ; patient history mild infusion reaction paclitaxel able continue receive paclitaxel corticosteroid premedications eligible participate , case likely related Cremophor paclitaxel Mifepristone may affect way body process type drug take onstudy . These include limited nonsteroidal antiinflammatory drug ( NSAIDs ) warfarin , cyclosporine , certain benzodiazepine . The study doctor review patient 's current medication determine prohibit study . Uncontrolled intercurrent illness psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue patient wish participate study Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible No history longterm ongoing short term use corticosteroid allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>